Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Novartis builds its case for novel MS treatment ofatumumab
biosimilar competition in the US and Europe.
Latest news
-
Roche cites COVID-19 and biosimilars in Q2 decline
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab). ... We originally had predicted a biosimilar impact of
-
EU grants approval for Venclyxto/Gazyvaro combo in CLL
It remains to be seen whether the draw of chemo-free therapy will be enough to offset the increased cost of the two drugs, and the availability of biosimilar versions of
-
Centre for Innovation in Regulatory Science awarded $1.09m Gates Foundation grant
According to CIRS, these inefficiencies can also negatively affects the authorisation of competitive generic and biosimilar medicinal products, which can impact the costs and availability of medicines.
-
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
The Swiss drugmaker already has an SC version of Herceptin monotherapy on the market, but that hasn’t on its own stopped biosimilars of the drug eating into market share. ... Last year, sales of Herceptin were flat overall at around $7bn, but fell 16%
-
Botox strength bolsters Allergan ahead of AbbVie takeover
to biosimilar competition, so the strong fourth-quarter performance is a relief for the company.
More from news
Approximately 137 fully matching, plus 347 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
It faces multiple competitors across both oral and injectable therapies, as well as a stiff pricing environment due to the presence of generics and biosimilars. ... The drug must leverage its competitive profile as it will face significant competition
-
20 for 2020 – Five pharma leaders to watch in 2020
biosimilars and other lower-cost drugs and health concerns relating to vaping products.
-
20 for 2020 – Five pharma companies to watch
in 2023, and is starting to feel the effects of biosimilar competition to the brand in Europe. ... The latter is still low level, however, and biosimilars to Botox are thought to be some years off the market.
-
Will biosimilars ever catch on in the US?
Commitment issues. By most estimates, the US is about a decade behind the EU in terms of adopting biosimilars, with 90% of all global biosimilar sales occurring in EU countries, even ... Gottlieb, in remarks made at the release of the FDA’s Biosimilar
-
The Golden Goose
Biosimilar fail. Another stumbling block has been our over-reliance on market-based solutions to this problem, ie, generics. ... The thinking was at that time we’d solved the biosimilar problem, and here we are nine years later saying, no, we haven’t.
More from intelligence
Approximately 12 fully matching, plus 60 partially matching documents found.
Latest appointments
-
New hires at Bayer, Eisai and Accord Healthcare
and biosimilar specialists,” he added.
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
Are biobetters a market access opportunity?
This produces time pressure for biobetters to make it to market before a biosimilar, to avoid the downward price pressure a biosimilar creates. ... Moreover, biobetters will need to enter the market before the exclusivity period of the patented reference
-
How to weather the pricing competiton
deal. The simulated market becomes highly competitive with the entrance of a better value product and then later a biosimilar/generic competitor.
-
Launch Excellence 2020
In the past year, the competition in biosimilars and complex generics has complicated the launch landscape.
-
The 'winner takes all' pricing game
Conclusions. Pharmaceutical tendering will stay as a key procurement approach for pharmaceutical products, especially for hospital products but also in outpatient settings for generics/biosimilars or other segments of products with
-
How ready are you for launch?
Specifically, it has focused its efforts on increasing competition in biosimilars and complex generics, which are difficult to copy, in a bid to increase competition and drive down prices.
More from PMHub
Approximately 12 fully matching, plus 27 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- AI: the smart money is on the smart thinking
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Mesoblast expands compassionate use COVID-19 programme
- Novartis builds its case for novel MS treatment ofatumumab
- US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine
- UK agrees on COVID-19 vaccine deals with J&J and Novavax
- COVID-19 vaccine approval unlikely before November, says US NIH director
- Calliditas bets on PBC drug in Genkyotex buyout
- Emotion-driven clinical trial marketing: A missed opportunity?
- Speed kills
- Unleashing the Potential of Multichannel Digital Strategies in Healthcare
Latest intelligence
- Emotion-driven clinical trial marketing: A missed opportunity?
- Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Quick links
Infographics
